102 USD
-0.57 (-0.56%)
102.5 USD
+0.5 (+0.49%)
Overall IRMD gets a fundamental rating of 7 out of 10. We evaluated IRMD against 185 industry peers in the Health Care Equipment & Supplies industry. IRMD gets an excellent profitability rating and is at the same time showing great financial health properties. IRMD is not valued too expensively and it also shows a decent growth rate. These ratings would make IRMD suitable for quality investing!
1. Profitability
1.1 Basic Checks
- IRMD had positive earnings in the past year.
- IRMD had a positive operating cash flow in the past year.
- Each year in the past 5 years IRMD has been profitable.
- In the past 5 years IRMD always reported a positive cash flow from operatings.
1.2 Ratios
- IRMD's Return On Assets of 18.47% is amongst the best of the industry. IRMD outperforms 98.92% of its industry peers.
- IRMD has a better Return On Equity (21.54%) than 94.62% of its industry peers.
- IRMD's Return On Invested Capital of 19.30% is amongst the best of the industry. IRMD outperforms 97.31% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for IRMD is significantly above the industry average of 8.84%.
- The 3 year average ROIC (18.78%) for IRMD is below the current ROIC(19.30%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.47% | ||
| ROE | 21.54% | ||
| ROIC | 19.3% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
- IRMD has a Profit Margin of 26.31%. This is amongst the best in the industry. IRMD outperforms 95.70% of its industry peers.
- IRMD's Profit Margin has been stable in the last couple of years.
- IRMD has a better Operating Margin (30.87%) than 98.39% of its industry peers.
- IRMD's Operating Margin has improved in the last couple of years.
- The Gross Margin of IRMD (77.07%) is better than 89.25% of its industry peers.
- In the last couple of years the Gross Margin of IRMD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.87% | ||
| PM (TTM) | 26.31% | ||
| GM | 77.07% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IRMD is creating value.
- IRMD has more shares outstanding than it did 1 year ago.
- IRMD has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- IRMD has an Altman-Z score of 50.54. This indicates that IRMD is financially healthy and has little risk of bankruptcy at the moment.
- IRMD has a better Altman-Z score (50.54) than 99.46% of its industry peers.
- IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 50.54 |
ROIC/WACC1.93
WACC10%
2.3 Liquidity
- A Current Ratio of 6.64 indicates that IRMD has no problem at all paying its short term obligations.
- The Current ratio of IRMD (6.64) is better than 84.41% of its industry peers.
- A Quick Ratio of 5.72 indicates that IRMD has no problem at all paying its short term obligations.
- IRMD's Quick ratio of 5.72 is amongst the best of the industry. IRMD outperforms 85.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.64 | ||
| Quick Ratio | 5.72 |
3. Growth
3.1 Past
- IRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.75%, which is quite good.
- The Earnings Per Share has been growing by 13.92% on average over the past years. This is quite good.
- IRMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.91%.
- IRMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.71% yearly.
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
Revenue 1Y (TTM)12.91%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.69%
3.2 Future
- Based on estimates for the next years, IRMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.26% on average per year.
- Based on estimates for the next years, IRMD will show a quite strong growth in Revenue. The Revenue will grow by 8.97% on average per year.
EPS Next Y15.29%
EPS Next 2Y14.48%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue Next Year13.26%
Revenue Next 2Y11.69%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 56.04, IRMD can be considered very expensive at the moment.
- Based on the Price/Earnings ratio, IRMD is valued a bit cheaper than 69.35% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.47, IRMD is valued quite expensively.
- The Price/Forward Earnings ratio is 47.17, which means the current valuation is very expensive for IRMD.
- 70.43% of the companies in the same industry are more expensive than IRMD, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of IRMD to the average of the S&P500 Index (24.26), we can say IRMD is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 56.04 | ||
| Fwd PE | 47.17 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than 66.67% of the companies in the same industry.
- IRMD's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 69.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 93.01 | ||
| EV/EBITDA | 48.03 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- IRMD has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.67
PEG (5Y)4.03
EPS Next 2Y14.48%
EPS Next 3Y9.26%
5. Dividend
5.1 Amount
- IRMD has a yearly dividend return of 0.66%, which is pretty low.
- IRMD's Dividend Yield is rather good when compared to the industry average which is at 0.19. IRMD pays more dividend than 91.40% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.87, IRMD's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.66% |
5.2 History
- IRMD has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- IRMD pays out 39.59% of its income as dividend. This is a sustainable payout ratio.
DP39.59%
EPS Next 2Y14.48%
EPS Next 3Y9.26%
102
-0.57 (-0.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-03 2025-11-03/bmo
Earnings (Next)02-11 2026-02-11/bmo
Inst Owners57.86%
Inst Owner Change0.47%
Ins Owners36.79%
Ins Owner Change-0.63%
Market Cap1.30B
Revenue(TTM)80.51M
Net Income(TTM)21.18M
Analysts82.5
Price Target100.98 (-1%)
Short Float %3.85%
Short Ratio3.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.66% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.59%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.85%
Min EPS beat(2)1.27%
Max EPS beat(2)10.44%
EPS beat(4)3
Avg EPS beat(4)2.54%
Min EPS beat(4)-1.96%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)4.28%
EPS beat(12)10
Avg EPS beat(12)6.04%
EPS beat(16)14
Avg EPS beat(16)9.77%
Revenue beat(2)2
Avg Revenue beat(2)0.71%
Min Revenue beat(2)0.01%
Max Revenue beat(2)1.41%
Revenue beat(4)2
Avg Revenue beat(4)-0.08%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)1.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.25%
Revenue beat(12)6
Avg Revenue beat(12)-0.02%
Revenue beat(16)7
Avg Revenue beat(16)-0.16%
PT rev (1m)0%
PT rev (3m)34.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.13%
EPS NY rev (1m)0%
EPS NY rev (3m)0.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 56.04 | ||
| Fwd PE | 47.17 | ||
| P/S | 16.12 | ||
| P/FCF | 93.01 | ||
| P/OCF | 51.87 | ||
| P/B | 13.19 | ||
| P/tB | 13.66 | ||
| EV/EBITDA | 48.03 |
EPS(TTM)1.82
EY1.78%
EPS(NY)2.16
Fwd EY2.12%
FCF(TTM)1.1
FCFY1.08%
OCF(TTM)1.97
OCFY1.93%
SpS6.33
BVpS7.73
TBVpS7.47
PEG (NY)3.67
PEG (5Y)4.03
Graham Number17.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.47% | ||
| ROE | 21.54% | ||
| ROCE | 24.38% | ||
| ROIC | 19.3% | ||
| ROICexc | 43.34% | ||
| ROICexgc | 46.82% | ||
| OM | 30.87% | ||
| PM (TTM) | 26.31% | ||
| GM | 77.07% | ||
| FCFM | 17.33% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexgc growth 3Y-6.9%
ROICexgc growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score4
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1128.47% | ||
| Cap/Sales | 13.74% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 96.82% | ||
| Profit Quality | 65.85% | ||
| Current Ratio | 6.64 | ||
| Quick Ratio | 5.72 | ||
| Altman-Z | 50.54 |
F-Score4
WACC10%
ROIC/WACC1.93
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
EPS Next Y15.29%
EPS Next 2Y14.48%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue 1Y (TTM)12.91%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.69%
Revenue Next Year13.26%
Revenue Next 2Y11.69%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
EBIT growth 1Y16.55%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y194.31%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y98.66%
OCF growth 3Y31.53%
OCF growth 5Y20.16%
IRADIMED CORP / IRMD FAQ
Can you provide the ChartMill fundamental rating for IRADIMED CORP?
ChartMill assigns a fundamental rating of 7 / 10 to IRMD.
Can you provide the valuation status for IRADIMED CORP?
ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.
Can you provide the profitability details for IRADIMED CORP?
IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.
What are the PE and PB ratios of IRADIMED CORP (IRMD) stock?
The Price/Earnings (PE) ratio for IRADIMED CORP (IRMD) is 56.04 and the Price/Book (PB) ratio is 13.19.
Can you provide the financial health for IRMD stock?
The financial health rating of IRADIMED CORP (IRMD) is 9 / 10.